Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia.
Cancer Chemother Pharmacol
; 24 Suppl 1: S16-9, 1989.
Article
em En
| MEDLINE
| ID: mdl-2667787
ABSTRACT
Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Doenças da Medula Óssea
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Adolescent
/
Child
/
Humans
Idioma:
En
Revista:
Cancer Chemother Pharmacol
Ano de publicação:
1989
Tipo de documento:
Article